Skip to main content
Signal8

NORTHWEST BIOTHERAPEUTICS INC (NWBO) Form 10-Q — May 15, 2026

$NWBOForm 10-QFiled May 15, 2026, 4:34 PM ET0001104659-26-062661Original filing

Northwest Biotherapeutics reported a net loss of $3.1 million for the first quarter of 2026, driven by $4.9 million in R&D and $6.5 million in G&A expenses, partially offset by a $2.25 million litigation settlement gain and non-cash fair value adjustments. The company generated only $494,000 in revenue, primarily from research services, while burning through cash reserves that now stand at just $1.8 million against total liabilities of $118 million. Management explicitly disclosed substantial doubt about the company’s ability to continue as a going concern, citing insufficient liquidity to fund operations, capital expenditures, and working capital requirements for the next year.

Key figures

Eps
0
Revenue
494000
Total Debt
59429000
Cash Position
1786000
Shares Outstanding
1643343757
G And AExpense
6536000
R And DExpense
4858000
Settlement Gain
2250000
Interest Expense
2346000
Total Liabilities
118111000
Debt Extinguishment Loss
4756000
Convertible Notes Fair Value
38341000

Price after filing

1 day: 0.0%7 days: -7.6%30 days: -20.8%

Close on the filing date to close N calendar days later (from $0.25). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    NORTHWEST BIOTHERAPEUTICS INC (NWBO) Form 10-Q — May 15, 2026: AI Analysis | Signal8